Director/PDMR Shareholding

7 Apr 2008 12:14

IQE PLC07 April 2008 IQE plc ('IQE' or the 'Company') DIRECTORS' DEALINGS IQE was notified on 4 April 2008 that Dr Andrew Nelson, Chief Executive of IQEplc, transferred 20 million ordinary shares of IQE on 04 April 2008 from a trustnamed the Andrew Nelson Interest in Possession Trust into his own name. Thischange puts into effect personal tax planning measures and is as a consequenceof the changes in UK Capital Gains Tax implemented on 6 April 2008. Following this transfer Dr Nelson's sole beneficial interest in ordinary sharesof IQE, including the Andrew Nelson Interest in Possession Trust, remainsunchanged at 27,391,303 shares representing 6.4% of the issued share capital ofthe Company, being 431,043,197 ordinary shares of 1p each. Contacts: IQE plc +44 29 2083 9400Drew NelsonPhil RasmussenChris Meadows College Hill +44 20 7457 2020Adrian Duffield/Ben Way Noble & Company Limited +44 20 7763 2200John Llewellyn-Lloyd/ Sam Reynolds Panmure Gordon (UK) Limited +44 20 7459 3600Aubrey Powell/ Ashton Clanfield NOTE TO EDITORS IQE plc is the leading global supplier of advanced semiconductor wafers withproducts that cover a diverse range of applications. It is able to provide a'one stop shop' for the wafer needs of the world's leading compoundsemiconductor manufacturers, who in turn use these wafers to make the chipswhich form the key components of virtually every high technology system. IQE hasparticular focus on the growing global wireless sector for applicationsincluding; mobile handsets, wireless infrastructure, Wi-Fi, WiMAX, basestations, GPS and satellite communications; as well as for the opticalcommunication sector including; optical storage (CD, DVD), laser optical mice,laser printers & photocopiers, thermal imagers, leading-edge medical products,bar-coding, high efficiency LEDs and advanced solar cells. The manufacturers of these chips are increasingly seeking to outsource waferproduction to specialist foundries such as IQE in order to reduce overall wafercosts and accelerate time to market. IQE is unique in being able to supplywafers using all of the leading crystal growth technology platforms includingMetal Organic Vapour Phase Epitaxy (MOVPE) and Molecular Beam Epitaxy (MBE) andthe Group is able to leverage its global purchasing volumes to reduce the costof raw materials. IQE also provides bespoke R&D services to deliver customized materials forspecific applications and offers specialist technical staff to manufacture tospecification either at its own facilities or on the customer's own sites. Thisis backed by a strategy of duplicating each key product processes over multiplesites to assure customers of security of supply as well as provide compellingcustomer benefits in terms of flexibility and predictability of cost, therebysignificantly reducing operating risk. IQE operates six manufacturing facilities; two in Cardiff and one in MiltonKeynes in the UK; two more in Bethlehem, Pennsylvania and Somerset, New Jerseyin the USA; and its most recent acquisition in Singapore. The Group also has 11sales offices located in major economic centres worldwide. This information is provided by RNS The company news service from the London Stock Exchange